Dr. Rouzier will be reviews the literature that supports Low T3 levels and the incidence of cardiac events and overall cardiovascular mortality. T3 administration can reduce lipid profiles and improve diabetic patient outcomes as well as decrease cardiovascular events.
Objectives:
Upon completion of this workshop, the healthcare professional will be able to:
- Review the predictive roles of various thyroid hormones and their role in coronary syndromes and CVD mortality.
- Evaluate which thyroid hormone constitutes an independent predictor for an increase in mortality and which one does not.
- Discuss the hemodynamic effects of T3 vs T4.
- Demonstrate that low Free T3 levels increase CVD, atherosclerosis, and endothelial dysfunction.
- Identify how low thyroid function, but still in the normal range, adversely effect metabolism and development of IR and diabetes.
- Recall that even the TSH and free T4 within the normal range are associated with metabolic syndrome. The sample half-below the TSH median (with probably higher functional thyroid status) exhibited better metabolic and cardiovascular profiles.
- Discuss how even thyroid function and tests that are in the “normal” range can still have an adverse effect on health, CVD, and metabolic disease. Therefore, normal is not optimal.
- Review the data demonstrating that thyroid hormone levels throughout the range of normal thyroid function the lower the level of thyroid hormone, the worse the dyslipidemia and metabolic disorder. The opposite is true for higher levels. “So, why did you prescribe hormone if the labs were normal?”
- Evaluate the studies demonstrating that T3 administration reduces visceral fat; T4 did not. So, which one should we use, and the use of which one is against AACE guidelines?
